Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ELAN
ELAN logo

ELAN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
24.580
Open
24.160
VWAP
23.71
Vol
8.29M
Mkt Cap
11.81B
Low
22.910
Amount
196.54M
EV/EBITDA(TTM)
15.51
Total Shares
499.45M
EV
15.38B
EV/OCF(TTM)
26.65
P/S(TTM)
2.40
Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.
Show More

Events Timeline

(ET)
2026-05-06
06:40:00
Elanco Q1 Revenue $1.37B Beats Expectations
select
2026-05-06
06:40:00
Elanco Animal Health Raises FY26 Revenue Outlook to $5.01B
select

News

seekingalpha
9.5
05-06seekingalpha
Elanco Animal Health Q1 2026 Earnings Call Insights
  • Significant Growth: Elanco achieved a 10% organic constant currency revenue growth in Q1 2026, with revenues reaching $1.371 billion, exceeding market expectations and demonstrating the company's continued market share expansion in the pet health sector, thereby enhancing confidence in future growth.
  • Innovation-Driven Revenue: The company's innovation products contributed $287 million in revenue during the first quarter, with the full-year innovation revenue target raised to $1.2 billion, indicating that Elanco's ongoing investment in product innovation will provide a long-term competitive advantage.
  • Optimistic Financial Outlook: Elanco has raised its full-year organic constant currency growth expectation to 5% to 7%, alongside an adjusted EBITDA forecast increase to $975 million to $1.005 billion, reflecting management's confidence in future performance and strong market demand.
  • Debt Management Strategy: The company has improved its year-end net leverage target to 3.0x to 3.2x, indicating a priority on managing free cash flow, while continuing to focus on debt repayment and small tuck-in acquisition opportunities to enhance financial flexibility.
PRnewswire
9.5
05-06PRnewswire
Elanco Raises Full Year Outlook and Innovation Targets
  • Strong Financial Performance: In Q1 2026, Elanco reported total revenue of $1.371 billion, a 15% increase year-over-year, with Pet Health revenue reaching $710 million, up 12%, showcasing the company's robust performance under its innovation-led strategy.
  • Innovation-Driven Growth: The successful launches of new products like Zenrelia and Credelio Quattro have driven market share gains, particularly in the Pet Health and Farm Animal segments, which achieved revenue growth of 12% and 18% respectively, indicating the company's competitive edge in the market.
  • Significant EBITDA Improvement: Adjusted EBITDA for Q1 was $334 million, reflecting a 21% increase compared to the previous year, highlighting ongoing improvements in cost control and operational efficiency, which further bolster investor confidence.
  • Upgraded Full-Year Guidance: Elanco has raised its full-year revenue outlook for 2026 to between $5.010 billion and $5.085 billion, anticipating benefits from favorable foreign exchange rates and continued price growth, demonstrating the company's agility in a dynamic market environment.
seekingalpha
9.5
05-05seekingalpha
Elanco to Announce Q1 Earnings on May 6
  • Earnings Announcement Date: Elanco (ELAN) is set to announce its Q1 earnings on May 6 before market open, with a consensus EPS estimate of $0.34, reflecting an 8.1% year-over-year decline, which may impact investor sentiment.
  • Revenue Expectations: Analysts project Elanco's Q1 revenue to reach $1.28 billion, representing a 7.6% year-over-year increase, indicating sustained demand and strategic market expansion in the animal health sector.
  • Performance Beat Record: Over the past two years, Elanco has beaten EPS and revenue estimates 88% of the time, showcasing its stable performance and management capabilities, which may bolster investor confidence in future results.
  • Estimate Revision Dynamics: In the last three months, EPS estimates saw one upward revision and seven downward adjustments, while revenue estimates experienced three upward revisions and two downward adjustments, reflecting mixed market perceptions regarding the company's future performance.
PRnewswire
8.5
04-27PRnewswire
Elanco Secures FDA Emergency Use Authorization for Screwworm Treatment
  • Emergency Use Authorization: Elanco has received Emergency Use Authorization from the FDA for Negasunt Powder, allowing its use for the prevention and treatment of New World screwworm infestations, ensuring veterinarians and livestock producers have immediate access to effective treatment options should the pest be detected in the U.S.
  • EPA Exemption Support: Additionally, Elanco has secured a Section 18 Emergency Exemption from the EPA for Tanidil, enabling its use in various livestock species, which will enhance the livestock industry's ability to respond to potential infestations.
  • Distribution Channels: Negasunt Powder and Tanidil will be distributed through the U.S. Animal Plant Health Inspection Service (APHIS) and its National Veterinary Stockpile, ensuring timely access to necessary medications for producers to mitigate economic losses in the event of an infestation.
  • Education and Prevention Measures: Elanco emphasizes the importance of self-education for producers regarding New World screwworm prevention and encourages regular livestock inspections to facilitate early detection and treatment, thereby reducing tissue damage and mortality rates.
Newsfilter
8.5
04-27Newsfilter
Elanco Secures Emergency Authorization for New World Screwworm Treatment
  • Emergency Authorization Secured: Elanco has received Emergency Use Authorization (EUA) from the FDA for Negasunt Powder, ensuring veterinarians and livestock producers have immediate access to effective treatment options should the New World screwworm invade, thereby enhancing animal health management capabilities.
  • Product Support Expansion: In addition to Negasunt Powder, Elanco offers Tanidil and Catron IV, which help producers effectively prevent and treat New World screwworm infestations, thereby strengthening its competitive position in the animal health market.
  • Federal Agency Collaboration: The emergency authorizations from the FDA, EPA, and USDA reflect a rapid response to emerging animal health threats, demonstrating the government's strong commitment to protecting agriculture and animal health.
  • Education and Prevention Focus: Elanco emphasizes the need for producers to self-educate and stay informed about New World screwworm prevention and treatment protocols to enable early detection and intervention, thus minimizing animal losses and potential ecological risks.
CNBC
6.0
04-15CNBC
Latest Rating Changes on Wall Street
  • Apple's Positive Outlook: Wells Fargo reiterates Apple (AAPL) as overweight, anticipating better-than-expected iPhone demand and continued double-digit growth in services ahead of its earnings report, with a price target of $300.
  • SolarEdge Downgraded: Goldman Sachs downgrades SolarEdge (SEDG) from neutral to sell, citing elevated expectations and challenging valuation as key factors behind the downgrade.
  • Meta's Advertising Growth: Deutsche Bank maintains a buy rating on Meta (META), highlighting that its investments in AI are yielding increasing returns for advertisers, which supports accelerated advertising revenue growth.
  • Autodesk Positioned Well: Jefferies initiates coverage on Autodesk (ADSK) with a buy rating, noting its strong positioning in agentic AI and solid fundamentals, presenting an attractive risk/reward profile at current levels.
Wall Street analysts forecast ELAN stock price to rise
11 Analyst Rating
Wall Street analysts forecast ELAN stock price to rise
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
22.00
Averages
25.50
High
30.00
Current: 0.000
sliders
Low
22.00
Averages
25.50
High
30.00
JPMorgan
Chris Schott
maintain
$28 -> $30
AI Analysis
2026-05-07
New
Reason
JPMorgan
Chris Schott
Price Target
$28 -> $30
AI Analysis
2026-05-07
New
maintain
Reason
JPMorgan analyst Chris Schott raised the firm's price target on Elanco to $30 from $28 and keeps an Overweight rating on the shares.
Citi
Buy
maintain
$30 -> $31
2026-05-07
New
Reason
Citi
Price Target
$30 -> $31
2026-05-07
New
maintain
Buy
Reason
Citi raised the firm's price target on Elanco to $31 from $30 and keeps a Buy rating on the shares. The firm says the company reported a "clean beat-and-raise" Q1.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ELAN
Unlock Now

Valuation Metrics

The current forward P/E ratio for Elanco Animal Health Inc (ELAN.N) is 20.83, compared to its 5-year average forward P/E of 18.73. For a more detailed relative valuation and DCF analysis to assess Elanco Animal Health Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
18.73
Current PE
20.83
Overvalued PE
24.55
Undervalued PE
12.91

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
14.35
Current EV/EBITDA
11.55
Overvalued EV/EBITDA
17.66
Undervalued EV/EBITDA
11.04

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.90
Current PS
2.26
Overvalued PS
2.62
Undervalued PS
1.19

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

suitable for swing trade?
Intellectia · 31 candidates
Region: USVolume: >= 3,000,000Rsi Category: moderateBeta: HighRiskList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Month Price Change Pct: $-15.00 - $-3.00
Ticker
Name
Market Cap$
top bottom
ALLO logo
ALLO
Allogene Therapeutics Inc
550.94M
RKLB logo
RKLB
Rocket Lab Corp
34.69B
DNLI logo
DNLI
Denali Therapeutics Inc
2.88B
MU logo
MU
Micron Technology Inc
402.85B
NNDM logo
NNDM
Nano Dimension Ltd
355.47M
CIFR logo
CIFR
Cipher Digital Inc
5.57B
stock to swingtrade
Intellectia · 18 candidates
Market Cap: >= 5.00BBeta: HighRiskList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Predict Return: >= 3.0%Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
AAOI logo
AAOI
Applied Optoelectronics Inc
8.89B
ELAN logo
ELAN
Elanco Animal Health Inc
12.68B
GTLS logo
GTLS
Chart Industries Inc
9.92B
TTMI logo
TTMI
TTM Technologies Inc
11.22B
WCC logo
WCC
Wesco International Inc
13.47B
NTAP logo
NTAP
NetApp Inc
20.82B
best stock for swing trade today
Intellectia · 61 candidates
Region: USPrice: $10.00 - $100.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: $5.00 - $15.00One Week Rise Prob: 0 - 100One Week Predict Return: 0.0% - 100.0%Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
ZEPP logo
ZEPP
Zepp Health Corp
327.61M
XPRO logo
XPRO
Expro Group Holdings NV
2.07B
FCX logo
FCX
Freeport-McMoRan Inc
94.21B
AGI logo
AGI
Alamos Gold Inc
20.87B
GFI logo
GFI
Gold Fields Ltd
51.00B
VOR logo
VOR
Vor Biopharma Inc
640.24M
what stocks look ready for a breakout
Intellectia · 103 candidates
Market Cap: >= 2.00BRegion: USPrice: $10.00 - $120.00Relative Vol: >= 1.50New High Low: 52w_HighBeta: ModerateRisk, HighRisk, LowRisk, NegativeBetaList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Support Resistance Relationship: PriceBreakResistanceMonthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CSCO logo
CSCO
Cisco Systems Inc
326.12B
KO logo
KO
Coca-Cola Co
335.18B
CCL logo
CCL
Carnival Corp
45.23B
RF logo
RF
Regions Financial Corp
26.27B
KEY logo
KEY
KeyCorp
24.94B
CSX logo
CSX
CSX Corp
74.09B
what stock should I trade today
Intellectia · 19 candidates
Market Cap: >= 1000.00MPrice: $5.00 - $100.00Price Change Pct: >= $3.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
PSNY logo
PSNY
Polestar Automotive Holding UK PLC
1.21B
FORM logo
FORM
FormFactor Inc
5.43B
AXTI logo
AXTI
AXT Inc
1.11B
OCUL logo
OCUL
Ocular Therapeutix Inc
1.80B
BLBD logo
BLBD
Blue Bird Corp
1.58B
KLIC logo
KLIC
Kulicke and Soffa Industries Inc
2.89B
Best stock for this week
Intellectia · 92 candidates
Market Cap: >= 5.00BPrice: >= $-100.00Quarter Revenue Yoy Growth: >= 0.0%Analyst Consensus: Strong Buy, Moderate Buy, HoldList Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice, AbovePriceMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $2.00Ema 20: >= -100One Week Rise Prob: >= 55Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
PR logo
PR
Permian Resources Corp
13.28B
BKH logo
BKH
Black Hills Corp
5.53B
WPC logo
WPC
W.p. Carey Inc
14.98B
ELAN logo
ELAN
Elanco Animal Health Inc
12.14B
LPLA logo
LPLA
LPL Financial Holdings Inc
30.15B
IBRX logo
IBRX
Immunitybio Inc
6.02B
best stock to hold for 30 days
Intellectia · 81 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Month Rise Prob: >= 60One Month Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
SMFG logo
SMFG
Sumitomo Mitsui Financial Group Inc
134.12B
ROST logo
ROST
Ross Stores Inc
60.99B
YPF logo
YPF
YPF SA
14.29B
FE logo
FE
FirstEnergy Corp
26.90B
NI logo
NI
NiSource Inc
20.72B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
92.03B
best stock to open for the next 30 days
Intellectia · 83 candidates
Market Cap: >= 10.00BAnalyst Consensus: Strong Buy, Moderate BuyMoving Average Relationship: PriceAboveMA20One Month Rise Prob: >= 60One Month Predict Return: >= 5.0%
Ticker
Name
Market Cap$
top bottom
SMFG logo
SMFG
Sumitomo Mitsui Financial Group Inc
134.12B
ROST logo
ROST
Ross Stores Inc
60.99B
YPF logo
YPF
YPF SA
14.29B
FE logo
FE
FirstEnergy Corp
26.90B
NI logo
NI
NiSource Inc
20.72B
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
92.03B
bullish stocks under 60
Intellectia · 28 candidates
Market Cap: >= 5.00BPrice: <= $60.00Beta: HighRiskWeekly Average Turnover: >= 3,000,000Rsi 14: >= 50Moving Average Relationship: PriceAboveMA20Quarter Price Change Pct: >= $5.00Annual Eps Yoy Growth: >= 15.0%
Ticker
Name
Market Cap$
top bottom
NU logo
NU
Nu Holdings Ltd
83.54B
B logo
B
Barrick Mining Corp
82.80B
RKT logo
RKT
Rocket Companies Inc
59.75B
PAAS logo
PAAS
Pan American Silver Corp
24.15B
MRNA logo
MRNA
Moderna Inc
19.46B
HL logo
HL
Hecla Mining Co
19.35B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B

Whales Holding ELAN

P
PRIMECAP Management Company
Holding
ELAN
+17.53%
3M Return
F
Frontier Capital Management
Holding
ELAN
+12.77%
3M Return
B
Bowen, Hanes & Company, Inc.
Holding
ELAN
+6.25%
3M Return
S
Shapiro Capital Management LLC
Holding
ELAN
+6.13%
3M Return
D
Douglas Lane & Associates, LLC
Holding
ELAN
+5.92%
3M Return
H
Hardman Johnston Global Advisors LLC
Holding
ELAN
+2.04%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Elanco Animal Health Inc (ELAN) stock price today?

The current price of ELAN is 23.65 USD — it has decreased -1.5

What is Elanco Animal Health Inc (ELAN)'s business?

Elanco Animal Health Incorporated is an animal health company. The Company is engaged in delivering products and services to prevent and treat disease in farm animals and pets. It serves animals across species, including dogs, cats, cattle, poultry, swine and sheep. Its pet health products help pets live longer, healthier and more active lives. Its pet health portfolio is focused on parasiticides, dermatology, vaccines and pain/other therapeutics. It includes parasiticide portfolios in the pet health market based on indications, species and formulations, with products that protect pets from fleas, ticks and internal parasites. It offers Advantage, K-9 Advantix, Advocate, and AdTab, which are over-the-counter treatments for the prevention and elimination of fleas and ticks. Its farm animal products help producers improve animal health and wellbeing. It offers a farm animal portfolio of products for cattle including beef and dairy, poultry, swine and sheep.

What is the price predicton of ELAN Stock?

Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is25.50 USD with a low forecast of 22.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Elanco Animal Health Inc (ELAN)'s revenue for the last quarter?

Elanco Animal Health Inc revenue for the last quarter amounts to 1.37B USD, increased 14.92

What is Elanco Animal Health Inc (ELAN)'s earnings per share (EPS) for the last quarter?

Elanco Animal Health Inc. EPS for the last quarter amounts to 0.11 USD, decreased -15.38

How many employees does Elanco Animal Health Inc (ELAN). have?

Elanco Animal Health Inc (ELAN) has 9400 emplpoyees as of May 11 2026.

What is Elanco Animal Health Inc (ELAN) market cap?

Today ELAN has the market capitalization of 11.81B USD.